Trial Profile
A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Capmatinib (Primary) ; Erlotinib (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms GEOMETRY duo-1
- Sponsors Novartis Pharmaceuticals
- 03 Apr 2022 The trial has been completed in Italy, according to European Clinical Trials Database.
- 16 Dec 2021 The trial has been completed in France according to European Clinical Trials Database.
- 25 Nov 2019 Status changed from completed to discontinued.